Cited by 571Bacterial Infections and VaccinesMicrobial infections and disease researchNeonatal and Maternal Infections

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Trotter, Caroline L, Andrews, Nick J, Kaczmarski, Edward B, Miller, Elizabeth, Ramsay, Mary E·2004·The Lancet

Open this paper in CoChat — free account

Abstract

The meningococcal serogroup C conjugate (MCC) vaccine programme in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years). However, for children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vaccine fell to low levels after only 1 year. The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(04)16725-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
Miller, E. J., SALISBURY, D. M., & Ramsay, M. E. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00299-7 · Cited by 483
Self-citation
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
Ramsay, M. E., Andrews, N. J., Trotter, C. L., Kaczmarski, E. B., & Miller, E. (2003) · BMJ · doi:10.1136/bmj.326.7385.365 · Cited by 409
Self-citation
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
Ramsay, M. E., Andrews, N. J., Kaczmarski, E. B., & Miller, E. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03594-7 · Cited by 337
Self-citation
Estimating Haemophilus influenzae Type b Vaccine Effectiveness in England and Wales by Use of the Screening Method
Ramsay, M. E., McVernon, J., Andrews, N. J., Heath, P. T., & Slack, M. P. (2003) · The Journal of Infectious Diseases · doi:10.1086/376997 · Cited by 172
Self-citation
Antibody Persistence and Immunological Memory at Age 4 Years after Meningococcal Group C Conjugate Vaccination in Children in the United Kingdom
Borrow, R., Goldblatt, D., Andrews, N. J., Southern, J., Ashton, L., Deane, S., Morris, R., Cartwright, K. A. V., & Miller, E. (2002) · The Journal of Infectious Diseases · doi:10.1086/344324 · Cited by 114
Self-citation

Show all 5 references

Research works printed but not linked: 1

Quarterly Communicable Disease Reports on the COVER programme for childhood immunisation

Sorted by citations

Items 201–300 of 571

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
Pace, D., Snape, M. D., Westcar, S., Oluwalana, C., Yu, L., Begg, N. T., Wysocki, J., Czajka, H., Maechler, G., Boutriau, D., et al. (2008) · Archives of Disease in Childhood · doi:10.1136/adc.2007.136036 · Cited by 34
Development of medicines for children in Europe: ethical implications
Saint-Raymond, A., & Brasseur, D. J. (2005) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2004.11.008 · Cited by 35
Combined Conjugate Vaccines: Enhanced Immunogenicity with the N19 Polyepitope as a Carrier Protein
Baraldo, K., Mori, E., Bartoloni, A., Norelli, F., Grandi, G., Rappuoli, R., Finco, O., & Giudice, G. D. (2005) · Infection and Immunity · doi:10.1128/iai.73.9.5835-5841.2005 · Cited by 34
Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies
Sáfadi, M. A. P., & McIntosh, E. D. G. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.159 · Cited by 32
A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years
Vesikari, T., Forstén, A., Boutriau, D., Bianco, V., der Wielen, M. V., & Miller, J. M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22165 · Cited by 33
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
Knuf, M., Romain, O., Kindler, K., Walther, U., Tran, P. M., Pankow-Culot, H., Fischbach, T. J., Kieninger‐Baum, D., Bianco, V., Baine, Y., et al. (2013) · European Journal of Pediatrics · doi:10.1007/s00431-012-1924-0 · Cited by 32
Impact of vaccination on meningococcal epidemiology
Stefanelli, P., & Rezza, G. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1108502 · Cited by 32
An Assessment of the Screening Method to Evaluate Vaccine Effectiveness: The Case of 7-Valent Pneumococcal Conjugate Vaccine in the United States
Cohen, A. L., Taylor, T. H., Farley, M. M., Schaffner, W., Lesher, L. J., Gershman, K. A., Bennett, N. M., Reingold, A. L., Thomas, A. R., Baumbach, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041785 · Cited by 31
Avidity Determinations for Haemophilus influenzae Type b Anti-Polyribosylribitol Phosphate Antibodies
Romero‐Steiner, S., Holder, P. F., de León, P. G., Spear, W., Hennessy, T. W., & Carlone, G. M. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.9.1029-1035.2005 · Cited by 31
Population density profiles of nasopharyngeal carriage of 5 bacterial species in pre-school children measured using quantitative PCR offer potential insights into the dynamics of transmission
Thors, V. S., Morales‐Aza, B. M., Pidwill, G. R., Vipond, I. B., Muir, P., & Finn, A. H. R. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1090069 · Cited by 30
The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative
Sáfadi, M. A. P., Monteros, L. E. E. D. L., López, E. L., Sáez‐Llorens, X., Lemos, A. P., Moreno‐Espinosa, S., Ayala, S. G., Torres, J. P., de Moraes, J. C., & Vázquez, J. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.814879 · Cited by 30
Polysaccharide Vaccines: A Perspective on Non-Typhoidal Salmonella
Perera, S. R., Sokaribo, A. S., & White, A. P. (2021) · Polysaccharides · doi:10.3390/polysaccharides2030042 · Cited by 30
Meningococcal carriage in the A frican meningitis belt
The MenAfriCar consortium (2013) · Tropical Medicine & International Health · doi:10.1111/tmi.12125 · Cited by 30
Pneumococcal conjugate vaccines: emerging clinical information and its implications
Lockhart, S. P., Hackell, J. G., & Fritzell, B. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.4.553 · Cited by 30
Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom
McVernon, J., Ramsay, M. E., & McLean, A. R. (2007) · Epidemiology and Infection · doi:10.1017/s0950268807009168 · Cited by 30
Self-citation
Immunogenicity of a Fourth Dose of Haemophilus influenzae Type b (Hib) Conjugate Vaccine and Antibody Persistence in Young Children from the United Kingdom Who Were Primed with Acellular or Whole-Cell Pertussis Component-Containing Hib Combinations in Infancy
Southern, J., McVernon, J., Gelb, D., Andrews, N. J., Morris, R., Crowley-Luke, A., Goldblatt, D., & Miller, E. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00191-07 · Cited by 30
Self-citation
Monitoring the impact of vaccines postlicensure: new challenges, new opportunities
Schuchat, A., & Bell, B. P. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.4.437 · Cited by 29
Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial
Pace, D., Khatami, A., McKenna, J., Campbell, D., Attard-Montalto, S., Birks, J., Voysey, M., White, C., Finn, A., Macloed, E., et al. (2015) · BMJ · doi:10.1136/bmj.h1554 · Cited by 28
Persistence of Immunity Following a Booster Dose of Haemophilus Influenzae Type B-Meningococcal Serogroup C Glycoconjugate Vaccine
Khatami, A., Snape, M. D., John, T. M., Westcar, S., Klinger, C. L., Rollinson, L., Boutriau, D., Mesaros, N. E., Wysocki, J., Gałaj, A., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181f728fd · Cited by 29
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: A Phase II/III double-blind randomized controlled trial
Hirve, S. S., Bavdekar, A., Pandit, A., Juvekar, S. K., Patil, M., Préziosi, M., Tang, Y., Marchetti, E., Martellet, L., Findlow, H., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.004 · Cited by 29
Community Protection
Fine, P., Mulholland, K., Scott, J. A. G., & Edmunds, W. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00077-8 · Cited by 31
Evolving meningococcal immunization strategies
Sáfadi, M. A. P., Bettinger, J. A., Maturana, G. M., Enwere, G., & Borrow, R. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.979799 · Cited by 29
Immunogenicity and Reactogenicity of Primary Immunization With a Novel Combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine Coadministered With a Diphtheria–Tetanus–Acellular Pertussis–Hepatitis B–Inactivated Poliovirus Vaccine at 2, 4 and 6 Months
Torres, J. C. T., Moro, M., Ruíz-Contreras, J., Castro, J., Gómez-Campderá, J. A., Navarro, M. L., Merino, J., Martín‐Ancel, A., Roca, J., García-del-Rio, M., et al. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000247070.60063.09 · Cited by 29
Conjugate vaccines for preventing meningococcal C meningitis and septicaemia
Conterno, L. D. O., Filho, C. R. D. S., Rüggeberg, J. U., & Heath, P. T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001834.pub2 · Cited by 29
Retracted
The relationship between mucosal immunity, nasopharyngeal carriage, asymptomatic transmission and the resurgence of Bordetella pertussis
Gill, C. J., Rohani, P., & Thea, D. M. (2017) · F1000Research · doi:10.12688/f1000research.11654.1 · Cited by 28
Prevention of meningococcal serogroup C disease by NeisVac-C™
Borrow, R., & Findlow, J. (2009) · Expert Review of Vaccines · doi:10.1586/14760584.8.3.265 · Cited by 28
Meningococcal disease in travelers
Cramer, J. P., & Wilder‐Smith, A. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283574c06 · Cited by 28
Immunogenicity and Reactogenicity of a Booster Dose of a Novel Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine Given to Toddlers of 13–14 Months of Age With Antibody Persistence Up to 31 Months of Age
Torres, J. C. T., Moro, M., Merino, J., Gómez-Campderá, J. A., García-del-Rio, M., Jurado, A., Díez-Delgado, F. J., Omeñaca, F., García-Sicilia, J., Ruíz-Contreras, J., et al. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31816b4561 · Cited by 28
Which early ‘red flag’ symptoms identify children with meningococcal disease in primary care?
Haj-Hassan, T. A., Thompson, M. J., Mayon-White, R. T., Ninis, N., Harnden, A., Smith, L. F., Perera, R., & Mant, D. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x561131 · Cited by 28
Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial
van Ravenhorst, M. B., van der Klis, F. R. M., van Rooijen, D. M., Knol, M. J., Stoof, S. P., Sanders, E. A. M., & Berbers, G. A. M. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.06.053 · Cited by 27
Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines
Micoli, F., Stefanetti, G., & MacLennan, C. A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1201693 · Cited by 27
Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age
Nolan, T. M., Nissen, M. D., Naz, A., Shepard, J. S., Bedell, L., Hohenboken, M. J., Odrljin, T. M., & Dull, P. M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27051 · Cited by 27
Prevention of Infectious Diseases in Athletes
Luke, A. C., & d’Hemecourt, P. A. (2007) · Clinics in Sports Medicine · doi:10.1016/j.csm.2007.04.006 · Cited by 27
Meningococcal group C disease in Greece during 1993–2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians
Kafetzis, D. A., Stamboulidis, K., Tzanakaki, G., Kremastinou, J., Skevaki, C. L., Konstantopoulos, A., & Tsolia, M. N. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01704.x · Cited by 27
Prevention of Meningococcal Disease
Kimmel, S. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmx070004 · Cited by 27
Hajj vaccinations—facts, challenges, and hope
Ghany, M. A. E., Sharaf, H., & Hill-Cawthorne, G. A. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.05.024 · Cited by 27
Existing antibacterial vaccines
Mendoza, N., Ravanfar, P., Satyaprakah, A., Pillai, S., & Creed, R. (2009) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2009.01225.x · Cited by 27
Immunogenicity and Immunologic Memory of Meningococcal C Conjugate Vaccine in Premature Infants
Collins, C. L., Rüggeberg, J. U., Balfour, G., Tighe, H., Archer, M., Bowen‐Morris, J., Diggle, L., Borrow, R., Balmer, P., Buttery, J. P., et al. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000187027.45918.6a · Cited by 27
Childhood immunisation: what is the future?
Pollard, A. J. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.095760 · Cited by 27
The Future of Meningococcal Vaccines
Healy, C. M., & Baker, C. J. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000154438.37306.ab · Cited by 27
Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age
Ishola, D., Andrews, N. J., Waight, P., Yung, C.-F., Southern, J., Bai, X., Findlow, H., Matheson, M., England, A., Hallis, B., et al. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000750 · Cited by 26
Self-citation
Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine
Nolan, T. M., Richmond, P., Marshall, H. S., McVernon, J., Alexander, K., Mesaros, N. E., Aris, E., Miller, J. M., POOLMAN, J. T., & Boutriau, D. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181fcb2bf · Cited by 26
A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines
Sáfadi, M. A. P., Berezin, E. N., & Oselka, G. W. (2012) · Jornal de Pediatria · doi:10.2223/jped.2167 · Cited by 27
A New Combination Haemophilus influenzae Type B and Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine for Primary Immunization of Infants
Pace, D., Snape, M. D., Westcar, S., Hamaluba, M., Yu, L., Begg, N. T., Wysocki, J., Czajka, H., Maechler, G., Boutriau, D., et al. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31813429fa · Cited by 26
Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines
Hargreaves, J., Greenwood, B. M., Clift, C., Goel, A., Roemer-Mahler, A., Smith, J., & Heymann, D. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60687-9 · Cited by 26
Epidemiology, Molecular Characterization and Antibiotic Resistance of Neisseria meningitidis from Patients ≤15 Years in Manhiça, Rural Mozambique
Ibarz-Pavón, A. B., Morais, L., Sigaúque, B., Mandomando, I., Bassat, Q., Nhacolo, A., Quintó, L., Soriano‐Gabarró, M., Alonso, P. L., & Roca, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019717 · Cited by 26
Estimating Individual-Level Risk in Spatial Epidemiology Using Spatially Aggregated Information on the Population at Risk
Diggle, P. J., Guan, Y., Hart, A. C., Paize, F., & Stanton, M. C. (2010) · Journal of the American Statistical Association · doi:10.1198/jasa.2010.ap09323 · Cited by 23
Pneumococcal conjugate vaccine and pneumococcal common protein vaccines
Klugman, K. P., BLACK, S. B., Dagan, R., Malley, R., & Whitney, C. G. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00032-x · Cited by 27
Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood
Khatami, A., Peters, A., Robinson, H., Williams, N., Thompson, A., Findlow, H., Pollard, A. J., & Snape, M. D. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05354-11 · Cited by 25
Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy
Pezzotti, P., Miglietta, A., Neri, A., Fazio, C., Vacca, P., Voller, F., Rezza, G., & Stefanelli, P. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.06.002 · Cited by 25
Invasive meningococcal disease epidemiology and control measures: a framework for evaluation
Jaime, J., Möller, J., Getsios, D., Coudeville, L., El-Hadi, W., Chevat, C., Nguyễn, V. H., & Caro, I. (2007) · BMC Public Health · doi:10.1186/1471-2458-7-130 · Cited by 25
Challenges and progress in the development of a serogroup B meningococcal vaccine
Lewis, S., Sadarangani, M., Hoe, J. C., & Pollard, A. J. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.30 · Cited by 25
Recent developments in Neisseria meningitidis group A conjugate vaccines
Frasch, C. E. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.2.273 · Cited by 25
Author names and affiliations
Zhang, Y., Banks, C. J., & Heaven, S. (2012) · Cited by 24
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
van der Vliet, D., Vesikari, T., Sandner, B., Martinón‐Torres, F., Muzsay, G., Forstén, A., Adelt, T., González, C. D., Simko, R., Bchir, S., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821000261 · Cited by 24
Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States
Banzhoff, A. (2017) · Therapeutic Advances in Vaccines · doi:10.1177/2051013616681365 · Cited by 24
Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs
Htar, M. T. T., Jackson, S., Balmer, P., Serra, L., Vyse, A., Slack, M., Riera-Montes, M., Swerdlow, D. L., & Findlow, J. (2020) · BMC Public Health · doi:10.1186/s12889-020-09946-1 · Cited by 23
Cost-Effectiveness Analysis of a Universal Infant Immunization Program with Meningococcal C Conjugate Vaccine in Brazil
de Soárez, P. C., Sartori, A. M. C., Nóbrega, L. A. L., Itria, A., & Novaes, H. M. D. (2011) · Value in Health · doi:10.1016/j.jval.2011.05.045 · Cited by 24
Timing of an Adolescent Booster after Single Primary Meningococcal Serogroup C Conjugate Immunization at Young Age; An Intervention Study among Dutch Teenagers
Stoof, S. P., van der Klis, F. R. M., van Rooijen, D. M., Knol, M. J., Sanders, E. A. M., & Berbers, G. A. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100651 · Cited by 23
Meningococcal conjugate vaccines
Pichichero, M. E. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.11.1475 · Cited by 23
Toward a Meningitis-Free World
BLACK, S. B., Pizza, M., Nissum, M., & Rappuoli, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003859 · Cited by 23
The Significance of the Intestinal Microbiome for Vaccinology: From Correlations to Therapeutic Applications
Harris, V. (2018) · Drugs · doi:10.1007/s40265-018-0941-3 · Cited by 24
Vaccine development against Neisseria meningitidis
Vogel, U. F., & Claus, H. (2010) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2010.00178.x · Cited by 23
Investigation of serum bactericidal activity in childhood and adolescence 3–6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine
Sakou, I.-I., Tzanakaki, G., Tsolia, M. N., Sioumala, M., Barbouni, A., Kyprianou, M., Papaevangelou, V., Τσίτσικα, Ά., Blackwell, C., Kafetzis, D. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.047 · Cited by 23
Effectiveness of Meningococcal C Conjugate Vaccine in Salvador, Brazil: A Case-Control Study
Cardoso, C. W., Ribeiro, G. S., dos Reis, M. G., Flannery, B. L., & Reis, J. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123734 · Cited by 22
B Cell Memory to a Serogroup C Meningococcal Conjugate Vaccine in Childhood and Response to Booster: Little Association with Serum IgG Antibody
Perrett, K. P., Jin, C., Clutterbuck, E., John, T. M., Winter, A. P., Kibwana, E., Yu, L., Curtis, N. C., & Pollard, A. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200451 · Cited by 22
Genome-based study of a spatio-temporal cluster of invasive meningococcal disease due to Neisseria meningitidis serogroup C, clonal complex 11
Stefanelli, P., Fazio, C., Neri, A., Ciammaruconi, A., Balocchini, E., Anselmo, A., Azzari, C., Rossolini, G. M., Vacca, P., Fortunato, A., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.05.003 · Cited by 22
Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic
LENNON, D. R., Reid, S., STEWART, J. M., Jackson, C. M., Crengle, S. M., & Percival, T. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2010.01969.x · Cited by 22
A Phase II, Randomized Study on an Investigational DTPw-HBV/Hib-MenAC Conjugate Vaccine Administered to Infants in Northern Ghana
Hodgson, A., Forgor, A. A., Chandramohan, D., Reed, Z. H., Binka, F. N., Bevilacqua, C., Boutriau, D., & Greenwood, B. M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002159 · Cited by 22
Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease
Hellenbrand, W., Koch, J., Harder, T., Bogdan, C., Heininger, U., Tenenbaum, T., Terhardt, M., Vogel, U. F., Wichmann, O., & von Kries, R. (2015) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-015-2253-z · Cited by 22
PREVENTION OF MENINGOCOCCAL DISEASE
Woodard, J. L., & Berman, D. M. (2006) · Fetal and Pediatric Pathology · doi:10.1080/15513810701209538 · Cited by 22
Immune Memory in Children Previously Vaccinated With an Experimental Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Pichichero, M. E., Papa, T., Blatter, M. M., Mitchell, D., Kratz, R., Sneed, J., Bassily, E. L., Casey, J. R., & Gilmet, G. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000243215.46312.4a · Cited by 22
Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups
Tsolia, M. N., Theodoridou, M., Tzanakaki, G., Vlachou, V., Mostrou, G., Stripeli, F., Kalabalikis, P., Pangalis, A., Kafetzis, D., Kremastinou, J., et al. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0155-6 · Cited by 22
IMMUNE RESPONSE AND ONE-YEAR ANTIBODY PERSISTENCE AFTER A FOURTH DOSE OF A NOVEL HAEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS SEROGROUPS C AND Y-TETANUS TOXOID CONJUGATE VACCINE (HibMenCY) AT 12 TO 15 MONTHS OF AGE
Marshall, G. S., Marchant, C. D., Blatter, M. M., Aris, E., Boutriau, D., POOLMAN, J. T., Friedland, L. R., & Miller, J. M. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181cdd379 · Cited by 21
Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil
Cordeiro, S. M., Neves, A. B., Ribeiro, C. T., Petersen, M. L., Gouveia, E. L., Ribeiro, G. S., Lôbo, T. S., Reis, J. N., Salgado, K., dos Reis, M. G., et al. (2007) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2007.06.012 · Cited by 21
Challenges and opportunities for meningococcal vaccination in the developing world
Shaker, R., Fayad, D., & Dbaibo, G. S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1434463 · Cited by 24
Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study
Piazza, F. M., Virta, M., Paassilta, M., Ukkonen, B., Ahonen, A., Esteves-Jaramillo, A., Forstén, A., Seppä, I., Ding, J., Neveu, D., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1902701 · Cited by 21
Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers
Jackson, C., LENNON, D. R., Wong, S., Yan, J., STEWART, J. M., Reid, S., Oster, P., Ypma, E., & Martin, D. (2011) · Archives of Disease in Childhood · doi:10.1136/adc.2009.180596 · Cited by 21
Clinical diagnoses and outcomes of 4619 hospitalised cases of laboratory-confirmed invasive meningococcal disease in England: Linkage analysis of multiple national databases
Edge, C., Waight, P., Ribeiro, S., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.07.016 · Cited by 21
Self-citation
Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination
van Ravenhorst, M. B., Marinović, A. B., van der Klis, F. R. M., van Rooijen, D. M., van Maurik, M., Stoof, S. P., Sanders, E. A. M., & Berbers, G. A. M. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.049 · Cited by 21
Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine
Bashir, H. E., Heath, P. T., Papa, T., Rüggeberg, J. U., Johnson, N., Sinha, R., Balfour, G., & Booy, R. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.12.018 · Cited by 21
The development of a new heptavalent diphtheria–tetanus–whole cell pertussis–hepatitis B–Haemophilus influenzae type b–Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components
GATCHALIAN, S. R., Palestroque, E., de Vleeschauwer, I., Han, H. H., POOLMAN, J. T., Schuerman, L., Dobbelaere, K., & Boutriau, D. (2007) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2007.08.007 · Cited by 21
TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines
Martinón‐Torres, F., Bosch, X. F., Rappuoli, R., Ladhani, S. N., Redondo, E., Vesikari, T., García‐Sastre, A., Calle, I. R., Rial, J. G., Salas, A., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1609823 · Cited by 21
Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease
Pollard, A. J., Green, C., Sadarangani, M., & Snape, M. D. (2013) · Archives of Disease in Childhood · doi:10.1136/archdischild-2012-303103 · Cited by 20
Antibody persistence and booster response 68 months after vaccination at 2–10 years of age with one dose of MenACWY-TT conjugate vaccine
Knuf, M., Helm, K., Kolhe, D. A., der Wielen, M. V., & Baine, Y. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.04.064 · Cited by 21
Importance of circulating antibodies in protection against meningococcal disease
Erlich, K. S., & Congeni, B. L. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.20473 · Cited by 20
ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE
Díez‐Domingo, J., Planelles, M. V., Baldó, J. M., Úbeda-Sansano, I., Jubert, A., Puig‐Barberà, J., & Gutiérrez-Gimeno, M. V. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181d9e653 · Cited by 20
Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age
Habermehl, P., Leroux-Roels, G. G., Sänger, R., Maechler, G., & Boutriau, D. (2010) · Human Vaccines · doi:10.4161/hv.6.8.12154 · Cited by 20
Effectiveness of Serogroup C Meningococcal Polysaccharide Vaccine: Results from a Case‐Control Study in Quebec
Wals, P. D., Deceuninck, G., Serres, G. D., Boivin, J., Duval, B., Remis, R. S., & Massé, R. (2005) · Clinical Infectious Diseases · doi:10.1086/428729 · Cited by 20
Neisseria meningitidisserogroup B bivalent factor H binding protein vaccine
Brendish, N. J., & Read, R. C. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1015997 · Cited by 19
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study
Dhingra, M. S., Namazova-Baranova, L. S., Arredondo-Garcı́a, J. L., Kim, K. H., Limkittikul, K., Jantarabenjakul, W., Алексеевна, П. О., Kobashi, I. A. R., Bae, C.-W., Ojeda, J., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821000698 · Cited by 19
Meningococcal Disease Awareness: Clinical and Epidemiological Factors Affecting Prevention and Management in Adolescents
Pelton, S. I. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2009.11.220 · Cited by 19
Polysaccharide–protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa
Clarke, E. T., Williams, N., Dull, P. M., Findlow, J., Borrow, R., Finn, A. H. R., & Heyderman, R. S. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.70 · Cited by 19
Can we, should we, eradicate the meningococcus?
Maiden, M. C. J., & Frosch, M. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.068 · Cited by 18
Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool
Stoof, S. P., van der Klis, F. R. M., van Rooijen, D. M., Bogaert, D., Trzciński, K., Sanders, E. A. M., & Berbers, G. A. M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.055 · Cited by 19
Effectiveness Analyses May Underestimate Protection of Infants after Group C Meningococcal Immunization
Vu, D. M., Kelly, D. F., Heath, P. T., McCarthy, N. D., Pollard, A. J., & Granoff, D. M. (2006) · The Journal of Infectious Diseases · doi:10.1086/505077 · Cited by 19
Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac® in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa
Viviani, S. (2022) · Vaccines · doi:10.3390/vaccines10040617 · Cited by 18
Meningococcal conjugate vaccines: optimizing global impact
Terranella, A., Cohn, A. C., & Clark (2011) · Infection and Drug Resistance · doi:10.2147/idr.s21545 · Cited by 19
The Capsule Polymerase CslB of Neisseria meningitidis Serogroup L Catalyzes the Synthesis of a Complex Trimeric Repeating Unit Comprising Glycosidic and Phosphodiester Linkages
Litschko, C., Romano, M. R., Pinto, V., Claus, H., Vogel, U. F., Berti, F., Gerardy‐Schahn, R., & Fiebig, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.678094 · Cited by 17
The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age
Rohner, G. B., Snape, M. D., Kelly, D. F., O’Connor, D., John, T. M., Clutterbuck, E., Ohene-Kena, B., Klinger, C. L., Odrljin, T. M., & Pollard, A. J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.03.036 · Cited by 18

Authors: Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E.
Affiliations: Manchester Royal Infirmary (GB)
ORCID: Trotter, Caroline L
Andrews, Nick J
Miller, Elizabeth
Ramsay, Mary E
Venue: The Lancet
Publisher: Elsevier BV
Published: 2004-07
Volume: 364
Issue: 9431
Pages: 365-367
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(04)16725-1
OpenAlex: W2160879811
Cited by: 571
References: 5
Citations by year: 2026: 1 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 12 · 2019: 15 · 2018: 18 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 27 · 2013: 29 · 2012: 42
FWCI: 50.77
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Explore Bristol Research (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
Keywords: vaccine effectiveness, long-term vaccine effectiveness, herd immunity, catch-up vaccination, meningococcal disease incidence, vaccination schedule, England
MeSH terms: Adolescent, Adult, Age Factors, Child, Child, Preschool, England, Follow-Up Studies, Humans, Immunization Schedule, Immunization, Secondary, Infant, Meningococcal Infections, Vaccines, Conjugate, Meningococcal Vaccines, Immunity, Herd, Neisseria meningitidis, Serogroup C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks